← Eichor
Study identifier: NCT06651294 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments

Condition: Urolithiasis  ·  Sponsor: Neopharm Bulgaria Ltd.

PhaseNA
Planned participants120
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy of a specialized formula of phytotherapeutic extracts (Neorenal Forte) aiding the complete elimination of residual fragments after fURS in adults.

This description comes directly from the study's public registry record.

Talk to the study team

Margarita Futekova  ·  +359 888 151 579  ·  m.futekova@neopharm.bg

Stefan Tunev, PhD  ·  +359 888 786 540  ·  s.tunev@neopharm.bg

Always discuss trial participation with your own doctor first.

Locations (9)

MHAT "Heart and Brain"Burgas, BulgariaRecruiting
UMHAT "Dr. Georgi Stranski"Pleven, BulgariaRecruiting
University Hospital for Active Treatment "Saint Marina"Pleven, BulgariaRecruiting
UMHAT "St. George"Plovdiv, BulgariaRecruiting
UMHAT KaspelaPlovdiv, BulgariaRecruiting
UMHAT "Alexandrovska"Sofia, BulgariaRecruiting
Military Medical AcademySofia, BulgariaRecruiting
UMBALSM "N. I. Pirogov"Sofia, BulgariaRecruiting
UMHAT "Sofiamed"Sofia, BulgariaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06651294